1. A method of selectively activating a chemical process for plasma-assisted chemical etch processing of a substrate in a processing chamber, the method comprising:
coupling energy into a process gas within the processing chamber to produce a plasma therein, the plasma containing positive ions;
applying a pulsed DC bias to the substrate positioned on a substrate support in the processing chamber; and
periodically biasing the substrate positioned on the substrate support between first and second bias levels, the first bias level being more negative than the second bias level,
wherein the substrate and substrate support, when biased at the first bias level, attracts mono-energetic positive ions from the plasma toward the substrate and is operable to enhance a selected chemical etch process at a surface of the substrate.
2. The method of claim 1, further comprising:
periodically biasing the substrate positioned on the substrate support at the second bias level, the periodic biasing having a magnitude and a duration configured to attract negative charges from the plasma toward the substrate and is operable to neutralize accumulated positive charge on the surface of the substrate.
3. The method of claim 2, wherein the substrate support includes a DC pulsed biased electrode positioned on one end of the processing chamber, the processing chamber further comprising:
an actively powered plasma generating electrode positioned on a side of the processing chamber opposing the DC pulsed biased electrode and configured to capacitively couple the energy into the process gas.
4. The method of claim 3, wherein the plasma generating electrode is DC powered, the method further comprising:
providing a grounding electrode in the processing chamber that is operably coupled to the plasma.
5. The method of claim 3, wherein the plasma generating electrode is RF powered and configured to capacitively couple energy into the process gas.
6. The method of claim 2, wherein said second bias level is established at a potential that minimizes the attraction of ions from the plasma toward the substrate with energies that are different from energies of ions attracted from the plasma toward the substrate when the first bias level is established.
7. The method of claim 1, wherein the pulsed DC bias is applied at a frequency that ranges from about 50 kHz to about 40 MHz.
8. The method of claim 7, wherein the pulsed DC bias is applied at a frequency that ranges from about 10 MHz to about 20 MHz.
9. The method of claim 1, further comprising:
providing a grounding electrode in the processing chamber that is operably coupled to the plasma.
10. The method of claim 9, further comprising:
applying a changing potential to the grounding electrode by one of switching a voltage potential applied to the grounding electrode, applying a pulsed DC voltage to the grounding electrode, or applying an AC voltage to the grounding electrode.
11. A plasma processing method, comprising:
supporting a substrate on a substrate support within a plasma processing chamber and at a first end thereof;
electrically energizing a plasma generating electrode at a second end of the processing chamber to capacitively couple energy into producing a plasma between the plasma generating electrode and the substrate, the second end opposing the first end; and
biasing the substrate on the substrate support with a pulsed DC waveform, the pulsed DC waveform applying a first voltage to the substrate for attracting positive ions from the plasma and onto the substrate and, periodically, applying a second voltage to the substrate that attracts electrons from the plasma and onto the substrate, the first voltage being more negative than the second voltage.
12. The plasma processing method of claim 11, wherein the pulsed DC waveform has a duty cycle ranging from about 1% to about 99%.
13. The plasma processing method of claim 11, wherein the pulsed DC waveform has a duty cycle selected so as to maintain mono-energetic ion energies while minimizing a charge-up effect on the substrate.
14. The plasma processing method of claim 11, wherein the plasma generating electrode is energized by an RF power source operating at 13.56 MHz.
15. The plasma processing method of claim 11, wherein the pulsed DC bias is applied at a frequency that ranges from about 10 MHz to about 20 MHz.
16. A plasma etching apparatus, comprising:
a plasma processing chamber;
a substrate support positioned within the plasma processing chamber and proximate a first end thereof;
a plasma generating electrode positioned proximate a second end of the plasma processing chamber, the second end opposing the first end;
a power supply operably coupled to the plasma generating electrode and configured to energize the plasma generating electrode so as to capacitively couple power into the plasma processing chamber to form a plasma between the substrate and the plasma generating electrode; and
a DC pulse generator operably coupled to the substrate support and configured to apply a pulsed DC bias voltage to a substrate on the substrate support,
wherein the DC pulse generator is configured to apply a first voltage to the substrate support that is operable to attract positive ions from the plasma and onto the substrate and, periodically, to apply a second voltage to the substrate support that is operable to attract electrons from the plasma and onto the substrate, the first voltage being more negative than the second voltage.
17. The plasma etching apparatus of claim 16, wherein the power supply operably coupled to the plasma generating electrode is an RF voltage source configured to operate at 13.56 MHz.
18. The plasma etching apparatus of claim 16, wherein the power supply operably coupled to the plasma generating electrode is a DC voltage source.
19. The plasma etching apparatus of claim 18, wherein the DC voltage source is electrically coupled to the plasma generating electrode via a relay switch.
20. The plasma etching apparatus of claim 16, wherein the plasma generating electrode further comprises a plurality of segments, each of the plurality of segments being electrically isolated from other segments of the plurality.
21. The plasma etching apparatus of claim 20, wherein the segments of the plurality are driven by the same power supply.
22. The plasma etching apparatus of claim 20, wherein the power supply operably coupled to the plasma generating electrode further comprises a plurality of power supplies, each of the plurality of power supplies being operably coupled to a respective one of the plurality of segments.
23. The plasma etching apparatus of claim 16, further comprising:
a grounded electrode operably coupled to a wall of the plasma chamber and positioned between the plasma generating electrode and the substrate support.
24. The plasma etching apparatus of claim 16, wherein the substrate support further comprises a plurality of segments, each of the plurality of segments being electrically isolated from other segments of the plurality.
25. The plasma etching apparatus of claim 24, wherein the segments of the plurality are driven by the same power supply.
26. The plasma etching apparatus of claim 24, wherein the DC pulse generator further comprises a plurality of DC generators, each of the plurality of DC generators being operably coupled to a respective one of the plurality of segments.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A method of enhancing apoptosis in one or more mammalian cells, comprising contacting the one or more cells with at least one mitochondrial-targeted chaperone inhibitor and at least one agent selected from the group consisting of: a death receptor agonist, an autophagy inhibitor, and a NF-\u03baB signaling pathway inhibitor, wherein the at least one mitochondrial-targeted chaperone inhibitor and the at least one agent are in an amount sufficient to enhance apoptosis in the one or more cells.
2. A method of treating of a proliferative disorder in a subject comprising administering to said subject at least one mitochondrial-targeted chaperone inhibitor and at least one agent selected from the group consisting of: a death receptor agonist, an autophagy inhibitor, and a NF-\u03baB signaling pathway inhibitor, wherein the at least one mitochondrial-targeted chaperone inhibitor and the at least one agent are administered in an amount sufficient to treat of a proliferative disorder in the subject.
3. A method for enhancing cancer or tumor cell death, the method comprising administering to the subject at least one mitochondrial-targeted chaperone inhibitor and at least one agent selected from the group consisting of: a death receptor agonist, an autophagy inhibitor, and a NF-\u03baB signaling pathway inhibitor, wherein the at least one mitochondrial-targeted chaperone inhibitor and the at least one agent are administered in an amount sufficient to enhance cancer or tumor cell death in a subject.
4. The method of claim 2, further comprising identifying a subject having cancer or a tumor andor determining whether cells of said cancer or tumor have increased mitochondrial concentrations of a chaperone as compared to a control cell.
5. The method of claim 2, wherein said proliferative disorder is a cancer.
6. The method of claim 5, wherein said cancer is selected from the group consisting of small-cell lung cancer, non-small cell lung cancer, colon cancer, colorectal cancer, and pancreatic cancer.
7. The method of claim 2, wherein the mitochondrial-targeted chaperone inhibitor is a composition comprising the formula:
A-B,
wherein A is a molecular chaperone inhibitor and B is a mitochondria-penetrating moiety and A and B are linked, optionally by a linking moiety, or a pharmaceutically acceptable salt thereof.
8. The method of claim 7, wherein A is a small molecule selected from the group consisting of an Ansamycin class Hsp90 inhibitor; a geldanamycin analogue Hsp90 inhibitor; a purine-scaffold class Hsp90 inhibitor; a resorcinol Hsp90 inhibitor; and a macrolactone-Hsp90 inhibitor; or is a peptide inhibitor of Hsp90 or a Shepherdin peptide comprising SEQ ID NO:2 (His-Ser-Ser-Gly-Cys), or comprises 17-allylamino-demethoxygeldamycin (17-AAG), radicicol, a purine-scaffold class Hsp90 inhibitor, or 17-dimethylaminogeldanamycin.
9. The method of claim 8, wherein A is a peptide inhibitor of Hsp90 that comprises a sequence that is at least 95% identical to SEQ ID NO:1 and binds to and inhibits Hsp90.
10. The method of claim 7, wherein B is selected from the group consisting of: a mitochondria penetrating peptide, an RNA mitochondrial penetrating signal, guanidine-rich peptoids, guanidine-rich polycarbamates, \u03b2-oligoarginines, and proline-rich dendrimers.
11. The method of claim 10, wherein B is a mitochondria penetrating peptide selected from the group consisting of: a mitofusin peptide, a mitochondrial targeting signal peptide, TAT peptide, Antennapedia helix III homeodomain cell-penetrating peptide (ANT) peptide, VP22 peptide, and Pep-1 peptide.
12. The method of claim 7, wherein B is selected from the group consisting of:
wherein:
R1 is H, alkyl, alkenyl, alkynyl, haloalkyl, aryl, arylalkyl, or RaRbRcSi;
Ra, Rb, and Rc are independently selected from alkyl or aryl; and
n is 0, 1, 2, 3, 4, 5, or 6;
wherein:
Ra, Rb, and Rc are independently selected from alkyl or aryl; and
n is 1, 2, or 3;
13. The method of claim 7, wherein A is
wherein:
R2 is H, alkyl, aryl, or arylalkyl; R3 is H, alkyl; and R4 is H, alkyl, alkenyl, aryl, arylalkyl, ORd, wherein Rd is H, alkyl, or arylalkyl.
14. The method of claim 8, wherein B comprises ANT or a mitochondrial-penetrating fragment thereof.
15. The method of claim 7, wherein the composition comprises a linking moiety between A and B.
16. The method of claim 15, wherein the linking moiety is selected from the group consisting of a peptide linker and a chemical linker.
17. The method of claim 15, wherein the linker moiety is divalent and selected from the group consisting of alkylene, alkenylene, alkynylene, cycloalkylene, arylene, heteroarylene, and peptide linker, wherein any two adjacent carbon-carbon bonds of said alkylene, alkenylene, or alkynylene, can be optionally replaced with one or more of O, NH, S, PRe, C(O)NRf, arylene, heterocycloalkylene, or heteroarylene; wherein Re and Rf are independently selected from alkyl or aryl.
18. The method of claim 15, wherein the linker moiety is
19. The method of claim 7, wherein A-B is:
wherein, R1 is H, alkyl, alkenyl, alkynyl, haloalkyl, aryl, arylalkyl, or RaRbRcSi;
R2 is H, alkyl, aryl, or arylalkyl; R3 is H, alkyl; R4 is H, alkyl, alkenyl, aryl, arylalkyl, ORd, wherein Rd is H, alkyl, or arylalkyl;
Ra, Rb, and Rc are independently selected from alkyl or aryl; and
n is an integer between 1 and 10, inclusive; or a pharmaceutically acceptable salt thereof.
20. The method of claim 7, wherein A-B is selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
21. The method of claim 7, wherein A-B is:
wherein, q is 1, 2, 3, 4, 5, or 6; and X is a pharmaceutically acceptable counter-ion.
22. The method of claim 2, wherein the death receptor agonist is an agonist of tumor necrosis factor (TNF)-related apoptosis-inducing ligand receptor 1 (TRAILR1), TRAILR2, CD95, tumor necrosis factor receptor 1 (TNFR1), death receptor 3 (DR3), DR6, ectodysplasin A receptor (EDAR), or nerve growth factor receptor (NGFR).
23. The method of claim 22, wherein said death receptor agonist is an agonist of TRAILR1 or TRAILR2.
24. The method of claim 23, wherein said death receptor agonist comprises an Apo2LTRAIL polypeptide.
25. The method of claim 24, wherein said Apo2LTRAIL is a fragment of the polypeptide of SEQ ID NO:17.
26. The method of claim 25, wherein said fragment comprises amino acids 114-281 of SEQ ID NO:17.
27. The method of claim 22, wherein the death receptor agonist comprises an antibody.
28. The method of claim 2, wherein the autophagy inhibitor is selected from the group consisting of: 3-methyladenine, bafilomycin A1, LY294002, wortmanin, hydroxychloroquine, chloroquine, 5-amino-4-imidazole carboxamide riboside, okadaic acid, a microcystin, microeystin, nodularin, analogues of cAMP, agents that elevate cAMP levels, adenosine, N6-mercaptopurine riboside, wortmannin, vinblastine, an antisense oligonucleotide, ribozyme, or siRNA that decreases the expression of MAP1LC3B, HSP90AA1, HSPA8, AMBRA1, ATG12, ATG16L1, ATG4A, ATG4B, ATG4C, ATG4D, ATG5, ATG9A, ATG9B, BECN1, GABARAP, GABARAPL1, GABARAPL2, IRGM, MAP1LC3A, RGS1, ULK1, ATG10, ATG16L1, ATG16L2, ATG3, ATG7, RAB24, DRAM, TMEM166, ATG3, AKT1, APP, ATG12, BAD, BAK1, BAX, BCL2, BCL2L1, BID, BNIP3, CASP3, CASP8, CDKN1B, CDKN2A, CLN3, CTSB, CXCR4, DAPK1, DRAM, EIF2AK3, FADD, FAS, HDAC1, HTT, IFNA2, IFNG, IGF1, INS, MAPK8, NFKB1, PIK3CG, PRKAA1, PTEN, SNCA, SQSTM1, TGFB1, TGM2, TNF, TNFSF10, CDKN1B, CDKN2A, IFNG, PTEN, RB1, TGFB1, TP53, TP73, EIF2AK3, IFNA2, IFNA4, IFNG, ARSA, CTSS, EIF4G1, ESR1, GAA, HGS, MAPK14, PIK3C3, PIK3R4, PRKAA2, RPS6KB1, TMEM74, TMEM77, ULK2, and UVRAG.
29. The method of claim 2, wherein the NF-\u03baB signaling inhibitor reduces I\u03baB\u03b1 phosphorylation andor degradation, NF-\u03baB nuclear translocation, NF-\u03baB binding to a KB promoter element, andor transactivation of transcription of an NF-\u03baB target gene.
30. Use of at least one mitochondrial-targeted chaperone inhibitor for the preparation of a medicament for treatment of a proliferative disorder.
31. A composition comprising at least one death receptor agonist, autophagy inhibitor, and NF-\u03baB signaling pathway inhibitor and at least one mitochondrial-targeted chaperone inhibitor.
32. A method of treating a therapeutic-resistant cancer in a subject, said method comprising administering to a subject having cancer cells resistant to a cancer therapeutic at least one mitochondrial-targeted chaperone inhibitor and the cancer therapeutic, wherein the at least one mitochondrial-targeted chaperone inhibitor and the cancer therapeutic are administered in amount sufficient to treat the therapeutic-resistant cancer.
33. The method of claim 32, further comprising identifying a subject as having a therapeutic-resistant cancer.
34. The method of claim 33, wherein the subject is identified by detecting an increase in NF-\u03baB signaling activity in a cancer cell in the subject.